Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Launches Biodefense Subsidiary

This article has been updated from a previous version to include comments from Invitrogen.


NEW YORK, July 13 (GenomeWeb News) - Invitrogen has spun out a subsidiary that will focus on biodefense applications, the company said today.


The subsidiary, called Biological Defense Systems, will be headquartered on Invitrogen's Frederick, Md., campus. BDS will build on Invitrogen's current product portfolio to develop detection kits for airborne, food-borne, and water-borne pathogens. Invitrogen said the spin-off would also work on vaccines and "other prophylactic measures" related to biodefense


The company has appointed James Meegan, a 13-year veteran of the National Institute of Allergy and Infectious Disease at NIH, to lead R&D at BDS as senior director of biodefense. James Gilmore, Invitrogen's current biodefense business segment director, will lead the commercial activities of the subsidiary.


Gilmore told GenomeWeb News that the subsidiary will be structured financially in a similar manner to that of Invitrogen's other subsidiaries, such as BioReliance. He declined to provide specifics about staffing plans for BDS, but said that "a dedicated sales staff and research group" are already in place in the 25,000-square-foot Frederick facility.


Gilmore said that BDS will focus on three primary areas: the research market, from which it will draw from its experience in pathogen research; vaccine and therapeutics development, which will be based on technology from the company's BioReliance, PanVera, and Gibco acquisitions; and PCR-based pathogen detection systems.


The subsidiary will allow Invitrogen to "capture various government contracts a little easier," Gilmore said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.